Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Angina Pectoris/MI
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Angina Pectoris/MI
    Cyclic Combined HRT Regimen via Patch, Gel Associated With Decreased Risk of MI - (DGNews)
    TopAbstracts in Angina Pectoris/MI 10/01/2008 - (DGNews)
    Drug-eluting or bare-metal stents for acute myocardial infarction - (N Engl J Med)
    Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis - (JAMA)
    Anticholinergics May Increase Risk of Cardiovascular Death, MI, or Stroke in COPD Patients - (DGNews)

    News archive

     Recent webcasts/CME - Angina Pectoris/MI
    • Late Breaking Data From Clinical Trials on RAAS Inhibition
    • Hyperglycemia in Acute Coronary Syndromes
      Do Angiotensin Receptor Blockers Increase the Risk of Myocardial Infarction?
      Non-STEMI
      Importance of Reducing Ischemic Time for Optimal Treatment of ST Elevation MI

      Webcasts/CME archive

       Recent cases - Angina Pectoris/MI
        Effort Angina in a Patient with Advanced Coronary Artery Disease. Role Played by Coronary Angiography, IVUS and Cardiac CT: Case Report
        A Case of Demand Ischemia from Phendimetrazine: A Case Report
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        The Effect of a Large Proximal Haemodialysis A-V Fistula on Weaning off Cardiopulmonary Bypass
        Diagnostic Uncertainty of Takotusbo Cardiomyopathy Presenting as Acute Myocardial Infarction in a Woman with Cardiovascular Risk Factors Hijacked at Gunpoint: A Case Report

        Cases archive
          




        my personal edition > angina pectoris/mi > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Atorvastatin as Effective as Amlodipine for Reducing Ischaemia in Patients With Chronic Stable Angina: Presented at ACC

          By Bruce Sylvester

          CHICAGO -- April 2, 2008 -- Atorvastatin monotherapy is as effective as amlodipine monotherapy and a combination of the two drugs for reducing transient myocardial ischaemia (TMI) in patients with chronic stable angina, researchers reported here at the 57th Annual Scientific Session of the American College of Cardiology (ACC 2008).

          "What we found, very unexpectedly, was that the statin was as effective an antianginal and anti-ischaemic drug as the traditional medications we use for treating angina and ischaemia.," said lead investigator John Deanfield, MD, Professor of Cardiology, University College, London, United Kingdom. "Within 18 weeks, the statin had virtually eliminated any evidence of ischaemia during the patient's normal daily activity."

          In the Double-Blind Atorvastatin Amlodipine (DUAAL) study, Dr. Deanfield and colleagues randomised subjects with coronary artery disease and chronic stable angina to atorvastatin (n=103), amlodipine (n=104), or a combination of the two drugs (n=104). Subjects also received usual care therapy for coronary artery disease, which included beta-blockers, long acting nitrates, and aspirin.

          The randomised, double-blind, parallel-group, multi-country trial had a 2-week run-in phase followed by 24 weeks of active therapy, titrated at week 6.

          At endpoint, the investigators reported that TMI episodes decreased by 66%, and 50% of all subjects became TMI free in all 3 groups. The investigators also reported a marked reduction in angina and nitroglycerin consumption.

          Notably, atorvastatin therapy was as effective as amlodipine for relief of TMI.

          In addition, the inflammation marker C-reactive protein decreased by 40% among atorvastatin subjects, with no change among amlodipine subjects.

          Adverse events were comparable across groups.

          "This is a novel finding, and one which will interest most physicians," said Dr. Deanfield.

          Funding for this study was provided by Pfizer, Inc.


          [Presentation title: Effect of Amlodipine, Atorvastatin and the Combination on Transient Myocardial Ischemia in Coronary Artery Disease From the DUAAL Study. Poster 1032-42]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send